Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Trial Title: Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

NCT ID: NCT05961124

Condition: Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
High Grade Ovarian Serous Adenocarcinoma

Conditions: Official terms:
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Cystadenocarcinoma, Serous
Niraparib

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Niraparib
Description: Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
Arm group label: Single arm- Niraparib

Other name: Zejula

Summary: The goal of this clinical trial is to test alternative dosing of niraparib in patients with newly diagnosed high-grade, advanced stage ovarian cancer. The main questions it aims to answer are: What is the incidence of hematologic and other adverse events? What is the incidence of dose interruption, dose reduction and discontinuation? What is the length of time of progression-free survival at 24 months?

Detailed description: This is a single arm phase II study in patients with newly diagnosed high-grade, advanced stage ovarian cancer. Patients must have received a minimum of 4 cycles of front-line platinum-based chemotherapy with a complete response or partial response (no measurable lesion >1 cm and normal cancer antigen (CA -25) after completion of chemotherapy) and primary or interval debulking surgery. This study aims to evaluate the incidence of hematologic and other adverse events and the incidence of dose interruption, dose reduction and discontinuation, and progression-free survival at 24 months with a niraparib dose escalation design. Study enrollment is planned to include 40 patients at one site.

Criteria for eligibility:
Criteria:
Inclusion Criteria 1. Patients must be able to understand the study, agree to participate and provide written, informed consent 2. Patients must be female and age >/= 18 years of age 3. Newly diagnosed, histologically confirmed, high-grade serous and grade 3 endometrioid ovarian, primary peritoneal, or fallopian tube cancer undergoing frontline treatment 4. Stage III and IV cancer according to International Federation of Gynecology and Obstetrics (FIGO) 2018 criteria and all patients undergoing neoadjuvant chemotherapy (NACT) 5. Patients must meet the following front-line treatment requirements: i. Patients must have completed a minimum of 4 cycles of platinum-based chemotherapy (carboplatin, cisplatin, oxaliplatin). Primary or interval debulking therapy and intraperitoneal chemotherapy are allowed. ii. Patients must have a complete response or partial tumor response (no lesion >1cm) to platinum-based regimen iii. CA-125 must be either: 1. CA-125 in normal range or 2. CA-125 decreased by 90% during front-line treatment and stable for a minimum of 7 days (does not increase by more than 15%) iv. Study drug can start within 12 weeks of completing chemotherapy 6. Patients must be post-menopausal with no menses for >1 year, or surgically sterilized, or willing to use adequate contraception to prevent pregnancy or abstain from intercourse and agrees not to donate eggs for the purpose of reproduction from study enrollment until 6 months following the last dose of treatment. i. Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin [hcg]) within 3 days prior to receiving the first dose of study treatment. 7. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 8. Patients must have adequate organ function at enrollment, as follows: i. Absolute neutrophil count >/= 1.5 x109/L ii. Platelets >/= 100 x109/L iii. Hemoglobin >/= 100 g/L without transfusion iv. Creatinine clearance >/= 60 mL/min using the Cockcroft-Gault equation v. Total bilirubin 4 weeks) or >/= grade 3 hematologic toxicity or fatigue from prior cancer therapy. 8. Patients with known history of myelodysplastic syndrome or pre-treatment cytogenetic testing at risk for myelodysplastic syndrome or acute myeloid leukemia 9. Patients receiving concurrent, prohibited medications 10. Patients with previous major surgery within 3 weeks of starting study treatment and must have recovered from any effects of previous surgery. 11. Patients with ascites drained within 4 weeks of starting study treatment 12. Patients receiving palliative radiotherapy to >20% of bone marrow within 2 weeks or any other radiotherapy within 1 week of study treatment 13. Patients receiving a transfusion (platelets or red blood cells) within 4 weeks of treatment 14. Patients planning to donate blood during the study or 90 days after treatment. 15. Patients with a diagnosis of another invasive cancer (other than ovarian cancer), within 2 years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated i. Patients with uncontrolled brain or leptomeningeal metastases. Controlled brain or leptomeningeal metastasis is defined as: ii. Central nervous system disease that has undergone treatment with radiation or chemotherapy > 1 month before study entry 16. No new or progressive signs or symptoms, stable steroid dose x 4 weeks or not taking steroids 17. Patients considered poor medical risk due to serious, uncontrolled medical disorder, non-malignant systemic disease, or active uncontrolled infection i. Patients with known HIV considered high risk for serious and fatal outcome 18. Patients with evidence of any condition, therapy, or laboratory abnormality that might confound study results or patient participation for full duration of study (Ex. Myelodysplastic syndrome, anemia, leukopenia, neutropenia, thrombocytopenia, etc) 19. Patients who are immunocompromised (Patients with splenectomy are allowed) 20. Patients with known, active hepatic disease (Ex. Hepatitis B or C), active biliary disease (exceptions for Gilbert's syndrome, asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease as per investigator assessment) 21. Patients with QT prolongation >470 milliseconds at screening 22. Patients with a known breast cancer susceptibility gene (BRCA1 and 2) mutation (as they routinely receive olaparib at our institution) If BRCA unknown they are not excluded. 23. Patients with a history of posterior reversible encephalopathy syndrome (PRES) 24. Patients who have had a live vaccine within 30 days of planned start date of study treatment 25. Patients with gastrointestinal abnormalities that may limit absorption 26. Patients with significant cardiovascular disease 27. Patients undergoing serial blood counts to achieve a value to meet eligibility 28. Patients receiving blood product transfusions in order to meet eligibility criteria

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Sunnybrook Research Institute

Address:
City: Toronto
Zip: M4N3M5
Country: Canada

Status: Recruiting

Contact:
Last name: Nithla Mohanathas
Email: nithla.mohanathas@sunnybrook.ca

Investigator:
Last name: Dr. Allan Covens, MD
Email: Principal Investigator

Start date: August 21, 2023

Completion date: September 2027

Lead sponsor:
Agency: Sunnybrook Health Sciences Centre
Agency class: Other

Collaborator:
Agency: GlaxoSmithKline
Agency class: Industry

Source: Sunnybrook Health Sciences Centre

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05961124